Superworth

Bristol-Myers Squibb price to free cash flow BMY

Market value divided by free cash flow over the last twelve months, since 2010.

Today, Oct 23, 2026
11.0×
10-year median
11.8×
Against its 10-year history
40th
percentile: 0 is its lowest day, 100 its highest
10-year range
6.1× to 111×
Peer median
18.9×

Bristol-Myers Squibb's price to free cash flow is 11.0× as of Oct 23, 2026.

That is below its ten-year median of 11.8×, close to the middle of its last ten years.

Over that time it ranged from 6.1× in Oct 2025 to 111× in Jan 2017.

The median for 9 large drugmakers of a similar size is 18.9×.

Price to free cash flow over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.0×7.1×12.0×
20257.3×6.1×8.9×
20248.5×6.4×9.1×
20238.9×8.7×12.9×
202212.0×9.4×13.6×
20219.3×8.4×12.9×
202012.0×11.0×19.4×
201913.8×11.8×22.7×
201822.4×18.3×26.7×
201722.7×22.2×111×
2016108×93.2×117×
2015108×28.6×108×
201428.6×19.3×37.6×
201335.6×7.7×35.8×
20127.3×7.3×14.0×
201113.2×10.7×13.3×
201012.1×11.3×13.0×

Against its peers

Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.

CompanyPrice to free cash flow
BMYBristol-Myers Squibb11.0×
PFEPfizer15.6×
GILDGilead Sciences14.9×
AMGNAmgen23.3×
MRKMerck22.3×
BIIBBiogen13.7×
ABBVAbbVie27.7×
JNJJohnson & Johnsonn/m
JAZZJazz Pharmaceuticals8.7×
LLYEli Lilly and65.9×
Peer median18.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Bristol-Myers Squibb

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.